Literature DB >> 1387303

Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.

F de Lalla1, R Maserati, P Scarpellini, P Marone, R Nicolin, F Caccamo, R Rigoli.   

Abstract

A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients. Mycobacteremia cleared in all patients by 2 to 8 weeks of treatment, and symptoms resolved. Four patients died; all had negative blood cultures until death, and disseminated M. avium-M. intracellulare complex infection was not considered the primary cause of death.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1387303      PMCID： PMC191622          DOI： 10.1128/AAC.36.7.1567

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs.

Authors:  D W Gjertson; P I Terasaki; S Takemoto; M R Mickey
Journal:  N Engl J Med       Date:  1991-04-11       Impact factor: 91.245

2.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients.

Authors:  J Hoy; A Mijch; M Sandland; L Grayson; R Lucas; B Dwyer
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

4.  Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.

Authors:  H Masur; C Tuazon; V Gill; G Grimes; B Baird; A S Fauci; H C Lane
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

5.  Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.

Authors:  L Heifets; P Lindholm-Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J J Pocidalo; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

7.  Comparative in-vitro activity of twenty antimicrobial agents against clinical isolates of Mycobacterium avium complex.

Authors:  N Khardori; K Rolston; B Rosenbaum; S Hayat; G P Bodey
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

8.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods.

Authors:  C B Inderlied; L S Young; J K Yamada
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

10.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191
View more
  14 in total

Review 1.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 2.  Drug treatment of HIV-related opportunistic infections.

Authors:  M E Klepser; T B Klepser
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Evaluation of the anti-rickettsial activity of fluoroquinolones.

Authors:  G Keren; A Itzhaki; C Oron; A Keysary
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice.

Authors:  T Lazard; C Perronne; Y Cohen; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium.

Authors:  D M Yajko; C A Sanders; J J Madej; V L Cawthon; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium.

Authors:  T Lazard; C Perronne; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

Review 8.  Mycobacterium avium complex: advances in therapy.

Authors:  D V Havlir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 9.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 10.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.